Literature DB >> 12429576

Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators.

Carl Guévin1, Josée Michaud, Judith Naud, Francois A Leblond, Vincent Pichette.   

Abstract

1. Chronic renal failure (CRF) is associated with a decrease in liver cytochrome p450 (p450). The mechanism remains poorly understood. The present study aimed to investigate the effects of the serum of rats with CRF on liver p450. 2. Normal rat hepatocytes were incubated for 24 h with serum (concentration of 10%) from rats with CRF and from control animals in order to measure (1). total p450 level, (2). protein expression and mRNA levels of major p450 isoforms, and (3). some of their specific metabolic activities (N-demethylation of erythromycin). Time-course experiments (incubation time from 12 to 48 h) and dose-response curves (concentration of serum ranging from 1 to 30%) have been conducted. 3. In normal hepatocytes incubated for 24 h with serum (concentration of 10%) from rats with CRF, total p450 level, protein expression and mRNA levels of several p450 isoforms (CYP2C6, 2C11, 3A1 and 3A2) were decreased by more than 35% (P<0.001) compared to serum from control animals. The protein expression as well as the mRNA levels of CYP2D were similar in hepatocytes incubated with serum from either control or CRF rats. The N-demethylation of erythromycin was decreased by more than 35% (P<0.001) in hepatocytes incubated with serum from rats with CRF. The inhibitory effect of serum from rats with CRF tended to peak at 48 h of incubation and was maximum at a concentration of 20%. 4. In conclusion, uremic serum contains mediator(s) that down-regulate the cytochrome p450 of normal hepatocytes secondary to reduced gene expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429576      PMCID: PMC1573574          DOI: 10.1038/sj.bjp.0704951

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

Review 1.  Preparation of isolated rat liver cells.

Authors:  P O Seglen
Journal:  Methods Cell Biol       Date:  1976       Impact factor: 1.441

2.  Enzyme induction in the uremic liver.

Authors:  H W Leber; L Gleumes; G Schütterle
Journal:  Kidney Int Suppl       Date:  1978-06       Impact factor: 10.545

3.  Drug dosing in renal insufficiency.

Authors:  R L Talbert
Journal:  J Clin Pharmacol       Date:  1994-02       Impact factor: 3.126

4.  Hepatic drug metabolism in rats with experimental chronic renal failure.

Authors:  S E Patterson; V H Cohn
Journal:  Biochem Pharmacol       Date:  1984-03-01       Impact factor: 5.858

Review 5.  Renal disease and drug metabolism: an overview.

Authors:  T P Gibson
Journal:  Am J Kidney Dis       Date:  1986-07       Impact factor: 8.860

6.  A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8.

Authors:  R Ziesche; M Roth; E Papakonstantinou; M Nauck; W H Hörl; M Kashgarian; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

7.  Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.

Authors:  Z Abdel-Razzak; P Loyer; A Fautrel; J C Gautier; L Corcos; B Turlin; P Beaune; A Guillouzo
Journal:  Mol Pharmacol       Date:  1993-10       Impact factor: 4.436

Review 8.  The effect of renal failure on hepatic drug clearance.

Authors:  M A Touchette; R L Slaughter
Journal:  DICP       Date:  1991-11

9.  Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.

Authors:  K Konishi
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

10.  Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.

Authors:  N Terao; D D Shen
Journal:  J Pharmacol Exp Ther       Date:  1985-05       Impact factor: 4.030

View more
  30 in total

1.  Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.

Authors:  C J Kirwan; I A M MacPhee; T Lee; D W Holt; B J Philips
Journal:  Intensive Care Med       Date:  2011-10-18       Impact factor: 17.440

Review 2.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 3.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

5.  Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Authors:  Reiner Frey; Corina Becker; Sigrun Unger; Anja Schmidt; Georg Wensing; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

6.  Reduced hepatic synthesis of calcidiol in uremia.

Authors:  Josée Michaud; Judith Naud; Denis Ouimet; Christian Demers; Jean-Luc Petit; Francois A Leblond; Alain Bonnardeaux; Marielle Gascon-Barré; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

Review 7.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

8.  Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics.

Authors:  Maribel Reyes; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2011-05-26       Impact factor: 3.534

Review 9.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

10.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Authors:  Thomas D Nolin; Reginald F Frye; Phuong Le; Hooman Sadr; Judith Naud; Francois A Leblond; Vincent Pichette; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.